CR
CRVO.US CervoMed Inc.
- Market cap
- USD 25.6M
- P/E
- -
- P/B
- 1.60x
- ROE
- -157.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CRVO.US undervalued?
Graham numberThe Graham number of CervoMed Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
CervoMed Inc. fundamental analysis
No fundamental analysis for CervoMed Inc. yet.
CervoMed Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About CervoMed Inc.
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood"brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical develop…
Full company profileCervoMed Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
CervoMed Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 7.15M | 9.74M | 4.01M | 0.00 |
| Gross Profit | -25.3K | -68.0K | -110K | -97.9K | -103K | -93.4K | -1.34M | -1.29M | -9.06M | - | - |
| Operating Income | -14.9M | -11.3M | -12.0M | -11.6M | -16.0M | -24.7M | -16.0M | -7.81M | -18.2M | -28.3M | -27.9M |
| EBITDA | -18.3M | 566K | -18.7M | -11.4M | -15.8M | -15.9M | -3.48M | -2.17M | -16.3M | -27.0M | -27.5M |
| Net Income | -18.0M | -1.37M | -18.4M | -11.8M | -14.2M | -24.1M | -15.6M | -2.17M | -16.3M | -27.0M | -27.2M |
| EPS | -1,983 | -120 | -425 | -132 | -20 | -19 | -30 | -0.82 | -2.02 | -2.98 | -1.80 |
| Balance Sheet | |||||||||||
| Total Assets | 17.5M | 26.1M | 18.2M | 24.3M | 27.7M | 37.8M | 4.16M | 9.97M | 43.1M | 22.9M | 21.3M |
| Total Liabilities | 8.30M | 4.92M | 2.59M | 4.14M | 2.92M | 2.93M | 13.2M | 2.60M | 3.88M | 4.66M | 3.97M |
| Shareholders' Equity | 9.18M | 21.2M | 15.6M | 20.1M | 24.8M | 34.9M | -9.00M | 7.38M | 39.2M | 18.2M | 17.4M |
| Cash & Short-term Investments | 1.55M | 8.90M | 7.99M | 14.2M | 18.5M | 37.3M | 4.09M | 7.79M | 38.9M | 20.9M | 19.6M |
| Total Debt | 2.43M | 550K | - | 247K | 149K | 10.0M | 12.4M | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -10.8M | -12.3M | -10.8M | -9.86M | -13.6M | -14.5M | -2.57M | -7.45M | -16.5M | -23.4M | -26.7M |
| Capital Expenditure | 2.33K | 448K | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 3.00 | 3.00 | 0.00 | 0.00 |
| Free Cash Flow | -10.8M | -12.8M | -10.8M | -9.86M | -13.6M | -14.5M | -2.57M | -7.45M | -16.5M | -23.4M | -26.7M |
| Ratios | |||||||||||
| ROE | -196.4% | -6.4% | -117.7% | -58.6% | -57.2% | -69.0% | - | -29.4% | -41.6% | -148.0% | -157.0% |
| ROA | -103.2% | -5.2% | -100.9% | -48.6% | -51.2% | -63.7% | -375.0% | -21.8% | -37.8% | -117.9% | -127.7% |
| Net Profit Margin | - | - | - | - | - | - | - | -30.4% | -167.3% | -673.1% | - |
| Debt to Equity | 0.26x | 0.03x | - | 0.01x | 0.01x | 0.29x | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
CervoMed Inc. dividends
CervoMed Inc. has not paid dividends in the last 9 fiscal years.
Last stock split: 2:3 on Aug 17, 2023.
Who owns CervoMed Inc.
- Insiders 26.42%
- Institutions 22.44%
- Public & others 51.14%
- Shares outstanding 15.1M
- Free float 9.61M
Top funds holding CRVO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 250K | 1.65% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 46.3K | 0.31% | -36.28% | Sep 2026 |
| Abante Quant Value FI | 38.3K | 0.25% | 0.00% | Aug 2026 |
| iShares Micro-Cap ETF | 29.3K | 0.19% | 0.00% | Oct 2026 |
| Fidelity Total Market Index | 9.02K | 0.06% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 8.99K | 0.06% | 0.00% | Sep 2026 |
| Avantis US Small Cap Equity ETF | 3.28K | 0.02% | 0.00% | Oct 2026 |
| Vanguard U.S. Eq Idx £ Acc | 2.60K | 0.02% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 2.50K | 0.02% | 0.00% | Aug 2026 |
| 1290 VT Micro Cap K | 2.18K | 0.01% | +103.93% | Sep 2026 |
| JHVIT Total Stock Market Index I | 425.00 | 0.00% | 0.00% | Aug 2026 |
| Global Core Equity UCITS ETF USD Acc | 125.00 | 0.00% | 0.00% | Oct 2026 |
Top institutions holding CRVO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Woodline Partners LP | 689K | 4.56% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 316K | 2.09% | 0.00% | Jun 2026 |
| Sabby Management LLC | 249K | 1.65% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 66.9K | 0.44% | -10.01% | Jun 2026 |
| BlackRock Inc | 53.8K | 0.36% | +4.23% | Jun 2026 |
| Byrne Asset Management LLC | 51.3K | 0.34% | +248.64% | Jun 2026 |
| Citizens Financial Group Inc | 37.5K | 0.25% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 36.2K | 0.24% | 0.00% | Jun 2026 |
| Jane Street Group LLC | 32.2K | 0.21% | +76.65% | Jun 2026 |
| Thompson Davis & Co Inc | 29.8K | 0.20% | +197.50% | Jun 2026 |
| Savvy Advisors Inc | 25.9K | 0.17% | 0.00% | Jun 2026 |
| Virtu Financial LLC | 24.1K | 0.16% | 0.00% | Jun 2026 |
| State Street Corp | 20.5K | 0.14% | 0.00% | Jun 2026 |
| Cetera Investment Advisers | 19.6K | 0.13% | -28.22% | Jun 2026 |
| Summit Financial LLC | 18.1K | 0.12% | 0.00% | Jun 2026 |
| Northern Trust Corp | 13.3K | 0.09% | -55.67% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 12.7K | 0.08% | -98.28% | Jun 2026 |
| HighTower Advisors, LLC | 11.9K | 0.08% | +5.81% | Jun 2026 |
| FMR Inc | 10.5K | 0.07% | -4.55% | Jun 2026 |
| Newbridge Financial Services Group, Inc. | 3.00K | 0.02% | 0.00% | Jun 2026 |
CervoMed Inc. company profile
- Company name
- CervoMed Inc.
- Ticker
- CRVO.US
- Exchange
- USA Stocks
- Listed since
- Jan 4, 2016
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 15
- Fiscal year end
- December
- Address
- 20 Park Plaza, Boston, MA, United States, 02116
- Phone
- 617 744 4400
- Website
- cervomed.com
About CervoMed Inc.
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood"brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
CervoMed Inc. management
8- Dr. John J. Alam M.D.Co-Founder, CEO, President & Director · born 1962
- Dr. Sylvie L. Gregoire Pharm.D.Co-Founder & Director · born 1961
- Mr. William Robert Elder J.D.CFO, General Counsel & Corporate Secretary · born 1983
- Ms. Kelly Blackburn M.H.A.Executive Vice President of Clinical Development · born 1964
- Dr. Marinus Verwijs Ph.D.Executive Vice President of Technical Operations · born 1976
- Dr. Mark A. De Rosch Ph.D.Executive VP of Regulatory, Government Affairs & Program Management · born 1964
- Dr. Claudia Ordonez M.D.Senior Vice President of Medical Science · born 1966
- Dr. Matthew Winton Ph.D.Chief Commercial & Business Officer · born 1978